[go: up one dir, main page]

WO2004108107A1 - Preparation pour la peau - Google Patents

Preparation pour la peau Download PDF

Info

Publication number
WO2004108107A1
WO2004108107A1 PCT/EP2004/005848 EP2004005848W WO2004108107A1 WO 2004108107 A1 WO2004108107 A1 WO 2004108107A1 EP 2004005848 W EP2004005848 W EP 2004005848W WO 2004108107 A1 WO2004108107 A1 WO 2004108107A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
skin
weight
composition according
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/005848
Other languages
German (de)
English (en)
Inventor
Wilfried Rähse
Ulrike Ruffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Priority to EP04739462A priority Critical patent/EP1651180A1/fr
Publication of WO2004108107A1 publication Critical patent/WO2004108107A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the invention relates to a preparation which is beneficial to the wellbeing of the skin, preferably skin lotion, its use, and a method for skin treatment, and a substrate impregnated with the agent.
  • the skin With an area of up to 2 m, the skin is the largest human body organ and is exposed to a wide range of harmful environmental influences.
  • the object of this invention is therefore a preparation which is beneficial to the skin and is to be applied to the skin, preferably skin lotion, characterized in that it contains one or more skin-protecting and / or skin-healing active substances and urea, with the proviso that the, preferably in the oils contained in the preparation as glycerol esters, ⁇ -linolenic acid content above 0.25% by weight, better above 0.35% by weight, preferably above 0.75% by weight, in particular above 1% by weight, preferably above 1.5% by weight, more preferably over 2% by weight, even more preferably over 2.5% by weight, particularly preferably over 3% by weight, very particularly preferably over 4% by weight, considerably preferred is above 5% by weight, very considerably preferably above 6% by weight and very preferably above 7% by weight, and that the content of at least twice, preferably polyunsaturated fatty acids, preferably in the oils and / or contained in the preparation or fats as a glycerol residue it bound, more than 0.5% by
  • the agent according to the invention advantageously enables active skin care in the form of stimulating skin regeneration, supporting skin physiology and strengthening the skin's barrier function.
  • the agent helps the skin to renew or keep its natural protective acid mantle intact.
  • the pH of the skin surface depends on sweat secretion, bacterial flora and the like. Talgzu- composition. Depending on the region of the skin, the pH is between 4 and 7, in particular around 5.5 for healthy skin.
  • Healthy human skin is characterized by the fact that its intact acid coat provides sufficient protection against microorganisms, germs and pathogens, that its buffering capacity and its alkali neutralizing capacity are sufficient to ward off harmful influences from surrounding fluids, that it acts as a barrier against the loss of
  • the body's own substances e.g. water, natural fats, electrolytes
  • Healthy skin is also characterized by the fact that it has a depot function for fat, water and blood and an important role in metabolism.
  • Skin healing in the context of the present invention is now everything that helps the skin to return to its original state. Everything that stimulates, trains, supports and encourages the skin's self-regulating powers is also curative, so that it is able to fulfill its functions by returning to its natural state of equilibrium. Furthermore, the term skin healing in the context of this invention means all influences which lead to obvious skin diseases such as eczema, rashes, redness, itching, swelling, blistering, oozing, crusts in various forms being at least alleviated, if not cured ,
  • skin protection in turn means everything that is necessary to maintain the normal performance of the skin with regard to its functions under specific stress situations and beyond its own protective mechanisms. This also clearly differentiates this term from skin care, because skin care only achieves a cosmetic benefit in terms of sensory needs.
  • skin protection supports the skin with additional agents that help the skin to fulfill its diverse functions, even under adverse conditions. Such adverse conditions can e.g. B. friction, cold, heat, UV radiation, aggressive ambient fluids, contact with skin-irritating materials.
  • the urea contained in the agents according to the invention promotes skin health in a variety of ways, since it can have an antimicrobial, water-binding, itch-relieving, skin-flaking, skin-smoothing effect and can inhibit excessive cell growth. It can also serve as a moisturizing factor for the skin, ie it can help the skin to retain moisture.
  • the agents contain at least 3% by weight, preferably at least 4% by weight, in particular at least 6% by weight, of urea, in each case based on the total composition.
  • ⁇ -Linolenic acid is present in the preparation in quantities of at least 0.25% by weight, based on the entire preparation, preferably bound as glycerol esters in the oils contained in the preparation.
  • ⁇ -linolenic acid and / or its full or partial glycerol esters help regulate and normalize trans-epidermal water loss through the skin and support normal skin functions.
  • At least twice, preferably polyunsaturated fatty acid is contained in amounts of at least 0.5% by weight, based on the total preparation, in the preparation, preferably bound as glycerol esters in the oils and / or fats contained in the preparation.
  • unsaturated fatty acids and / or their full or partial esters of glycerin have significant advantages. Saturated fatty acids are primarily broken down by the human organism in order to obtain energy and carbon compounds.
  • the body uses the at least two, preferably polyunsaturated fatty acids and / or their full or partial glycerol esters in particular to produce regulating, short-lived hormones, to maintain the immune system and to build new cell structures such as e.g. Membranes, since degraded or expelled cells are renewed volunteersly. So these unsaturated fatty acids and / or their full or partial glycerol esters have a very beneficial effect on the skin even when used externally.
  • the skin regeneration is supported or activated or stimulated by the agents.
  • the agents do not help the skin to dry out.
  • the skin is protected from premature aging.
  • the skin is smoothed and cared for.
  • the agents have an antiseptic effect.
  • the agents support wound and skin healing.
  • the agents alleviate skin irritation and itching.
  • the agents help to protect the skin's protective acid mantle bilize.
  • the agents produce an improved feeling on the skin that is perceptible over a very long period of time and give the skin an increased cosmetic elegance.
  • the agents are characterized by excellent skin tolerance.
  • the funds are absorbed quickly and have a long effect.
  • the agents regulate trans-epidermal water loss through the skin and help to normalize it if necessary.
  • the agent according to the invention is characterized in that it contains only natural ⁇ -linolenic acid sources, preferably hemp oil, borage oil, evening primrose oil, the core oil of black currant, echium oil, trichodesma oil and / or black cumin oil act as a ⁇ -linolenic acid source.
  • natural ⁇ -linolenic acid sources preferably hemp oil, borage oil, evening primrose oil, the core oil of black currant, echium oil, trichodesma oil and / or black cumin oil act as a ⁇ -linolenic acid source.
  • the seed oils of other species from the families of the Boraginaceae, Scrophulariaceae, Onagraceae and / or Saxifragaceae also serve as ⁇ -linolenic acid sources in a preferred embodiment.
  • Hemp oil usually has, preferably bound as glycerol ester, ⁇ -linolenic acid contents up to approx. 6% by weight, borage oil up to approx. 25% by weight, evening primrose oil up to approx. 10% by weight, the core oil of the black currant up to approx 20% by weight, black cumin oil to 1% by weight, echium oil to 10% by weight and trichodesm oil to 4% by weight.
  • the ⁇ -linolenic acid content depends on the respective cultivation of the vegetable raw material or on the seed variety, and can easily be higher or lower than the above-mentioned guide values.
  • the preferred oils hemp oil, echium oil, trichodesma oil, borage oil, evening primrose oil, the core oil of black currant and / or black cumin oil are not only characterized by their specific ⁇ -linolenic acid content, but also by their respective minor or trace components, which are often found in the hundreds can go and sometimes work synergistically together.
  • the beneficial effects of hemp oil, echium oil, trichodesm oil, borage oil, evening primrose oil, the core oil of black currant and / or beneficial to the skin Black cumin oil is additionally reinforced by these special minor or trace components.
  • hemp can contain tetrahydrocannabinol (THC), it is particularly advantageous if the hemp oil contained according to the invention is obtained from low-THC, preferably from THC-free hemp varieties, with low-THC hemp varieties having a THC content of less than 0.3% by weight. % exhibit. Suitable varieties are listed, for example, in the "Common EU Variety Catalog".
  • the agent according to the invention is characterized in that at least one of the active substances contained has an antiseptic effect or contains at least one antiseptic substance.
  • the attribute of antiseptic activity means an effect which is beneficial to the self-regulating powers of human skin. This effectiveness is not in its form with the classic germicidal or germicidal agents such. B. phenols, halogens, alcohols, with which, for. B. skin u. To compare mucous membranes, wounds or even medical instruments to achieve asepsis (sterility).
  • Classic antiseptics include antimicrobial measures at the point of origin or at the point of entry of a possible infection or at the focus of infection on the surface of the body.
  • the particular advantage of the antiseptically active substances which can be used according to the invention results from a synergistic interaction of these substances with the general functional mechanisms of humans Skin, since these mildly antiseptic substances z.
  • B. Reduce germs, including harmful germs, but do not destroy them completely, i.e. until they are sterile. So there are enough germs on the skin that are sufficient to train and strengthen the self-regulating powers of human skin.
  • the general functional mechanisms of the skin are supported by the interaction of the skin's self-regulating powers with the antiseptic capacity of the active substances contained in the agent. This is of great advantage especially with regard to already irritated and / or otherwise damaged skin.
  • the skin's self-regulating powers are sometimes no longer able, if only temporarily, to ensure skin health on its own.
  • These self-regulating forces are supported, trained and strengthened in synergistic interaction with the agents according to the invention and their use according to the invention.
  • the agent according to the invention supports the natural skin flora of humans.
  • compositions of such an embodiment serve their purpose particularly when the antiseptic agent is an oil, preferably an essential oil.
  • This antiseptically active oil is preferably essential oil, which is selected in particular from the group of Angeiica fine - Angelica archangelica, Anise - Pimpinella Anisum, Benzoe siam - Styrax tokinen- sis, Cabreuva - Myrocarpus fastigiatus, Cajeput - Melaleuca leucadendron, Cistus - Cistrus ladaniferus, Copaiba balsam - Copaifera reticulata, Costus root - Saussurea discolor, noble pine needle - Abies alba, Elemi - Canarium luzonicum, fennel - Foeniculum dulce spruce needle - Picea abies, geranium - Pelargonium camphora, leaves Immortelle (straw flower) Helichrysum ang., Extra ginger - Zingiber off., St.
  • Another advantage of the above-mentioned essential oils is their special multifunctionality, which, in addition to the mildly antiseptic activity described, results from a large number of other desirable organoleptic properties which can be attributed to these oils.
  • these oils are considered to have an expectorant effect, since they exert a mild, positive stimulus on the mucous membranes of the respiratory system.
  • a desirable feeling of warmth may arise.
  • Deodorant, pain-relieving, circulation-promoting, calming effects could be observed by the applicant in connection with the use of these designated oils according to the invention and recognized as particularly advantageous.
  • organoleptic properties of these oils are generally not shaped by the main components, but by the minor or trace components, which can often go into the hundreds and sometimes work together synergistically.
  • Another advantage in connection with the oils mentioned is their harmonizing fragrance and fragrance, which in many cases leads to positive feelings in people.
  • the agent according to the invention not only supports the natural skin flora of humans, but also helps the human organism to additional advantages of the kind just described.
  • tea tree oil in particular is of great advantage for the subject matter of the invention.
  • tea tree oil In addition to its remarkable germicidal, antiseptic, fungicidal, antiviral, wound healing, anti-inflammatory, scarring effects, it has excellent skin tolerance and offers a wide range of other uses, for example with regard to the supportive treatment of colds or rheumatic diseases, gout, muscle pain.
  • the rosemary oil is also particularly advantageous.
  • the agent according to the invention is characterized in that it contains terpene-containing plant extracts, preferably extracts from plants of the genera Leptospermum and Melaleuca from the family of the Myrtaceae and particularly preferably tea tree oil (extract from Melaleuca alternifolia) or oil from the kayeput tree (Melaleuca leucadendra).
  • tea tree oil extract from the leaves or parts of plants of the plant genera Leptospermum and Melaleuca, the natural range of which is restricted to the subtropical coastal regions of New South Wales, are preferably obtained by steam distillation or extraction. Leaves of the Australian tea tree (Melaleuca alternifolia) are particularly preferably used as starting products.
  • the invention Agents according to the invention characterized in that the terpene-containing plant extract is tea tree oil and is contained in the agent in an amount of 0.005-2% by weight.
  • oils mentioned, hemp oil, borage oil, echium oil, trichodesma oil, evening primrose oil, the core oil of black currant and / or black cumin oil are skin-protecting and / or skin-healing active substances in the sense of the invention.
  • an additional skin-protecting substance is used in addition to one or more of these oils (hemp oil, borage oil, echium oil, trichodesma oil, evening primrose oil, seed oil of black currant and / or black cumin oil).
  • This skin protecting substance is advantageously a skin protecting oil, e.g. B.
  • carrier oil especially selected from the group algae oil Oleum Phaeophyceae, aloe vera oil aloe vera brasiliana, apricot kernel oil Prunus armeniaca, arnica oil Arnica montana, avocado oil Persea americana, calendula oil Calendula officinalis, camellia oil Camellia oleiferus tinctor oil, tinel oil, distel peanut oil Arachis hypogaea, hazelnut oil Corylus avellana /, St.
  • carrier oil especially selected from the group algae oil Oleum Phaeophyceae, aloe vera oil aloe vera brasiliana, apricot kernel oil Prunus armeniaca, arnica oil Arnica montana, avocado oil Persea americana, calendula oil Calendula officinalis, camellia oil Camellia oleiferus tinctor oil, tinel oil, distel peanut oil Arachis hypogaea, hazelnut oil Cor
  • oils just listed are natural emollients, ie agents that make body tissues softer and more supple and reduce the roughness of the skin. On the one hand, these oils have a skin-care effect. On the other hand, these oils have other specific effects that require a synergistic interact with the skin and its self-regulating powers and provide protection even under adverse conditions.
  • a particularly preferred oil for the purposes of this invention is hemp oil.
  • Hemp oil which has a high proportion of essential fatty acids and also usually contains up to 6% by weight of the valuable ⁇ -linolenic acid (GLA), which is preferably bound as a glycerol ester, also has an anti-inflammatory, slightly pain-relieving, healing, nourishing effect, improves skin structure, prevents signs of aging , It improves tissue renewal processes and has a high regenerative effect on injured tissue.
  • GLA ⁇ -linolenic acid
  • it can increase the care properties or other properties of other oils, in particular all oils explicitly mentioned here.
  • hemp oil plays a special role in the sense of this invention as a result of its high GLA content In the event of impaired transepidermal water loss, topical treatment with GLA leads to a sharp reduction in transepidermal water loss. In addition, hemp oil shows other positive effects on the human organism with regard to arteriosclerosis, rheumanoid artritis, diabetic neuropathy and even heart problems.
  • Another preferred oil for the purposes of this invention is borage oil.
  • Black cumin oil, echium oil, trichodesma oil, evening primrose oil and the core oil of black currant are also preferred oils in the sense of the invention.
  • Evening primrose oil is also characterized by the fact that it is very easily absorbed by the skin and has anti-inflammatory properties.
  • Another preferred oil is meadowfoam oil. It is distinguished by the fact that it can enhance the action of other oils, which is why it is advantageously used in combination with other oils. It penetrates easily into the skin and does not leave an oily feeling. It has very good dispersion properties, is very stable to oxidation, and is rich in essential fatty acids and tocopherols.
  • Another preferred oil is wheat germ oil. It is distinguished by the fact that it can enhance the action of other oils, which is why it is advantageously used in combination with other oils. It has a high content of vitamin E and is characterized by its content of essential fatty acids.
  • almond oil is distinguished by the fact that it can enhance the action of other oils, which is why it is advantageously used in combination with other oils. It is a very stable oil with excellent cold stability.
  • avocado oil is distinguished by the fact that it can enhance the action of other oils, which is why it is advantageously used in combination with other oils. It has very good penetration properties and is extremely skin-friendly even with very sensitive skin.
  • the agent is characterized in that it has at least 2, preferably at least 3, oils selected from the group of hemp oil, borage oil, echium oil, trichodesma oil, evening primrose oil, seed oil from the blackish zen contains currant and / or black cumin oil, in particular in proportions of at least 1% by weight per oil, preferably 5% by weight per oil, preferably 7% by weight per oil, in each case based on the total composition.
  • the agent is characterized in that it contains evening primrose oil, preferably at least 7% by weight evening primrose oil, in particular at least 10% by weight evening primrose oil, based on the total agent, and a further oil selected from the group of hemp oil, borage oil, Contains Echium Oil, Trichodesma Oil, Black Currant Seed Oil and / or Black Cumin Oil.
  • the agent is characterized in that it contains hemp oil, preferably at least 7% by weight of hemp oil, in particular at least 10% by weight of hemp oil, based on the total agent, and a further oil selected from the group of evening primrose oil, echium oil, Trichodesma oil, borage oil, blackcurrant seed oil and / or black cumin oil.
  • the agent is characterized in that it contains hemp oil and evening primrose oil, preferably in proportions of at least 5% by weight, based on the total agent.
  • the agents according to the invention contain a minimum content of all oil component (s) of 15% by weight, preferably 20% by weight, in particular 25% by weight, preferably 30% by weight, particularly preferably 35% by weight, each based on the total mean.
  • the agents according to the invention contain a minimum content of the oils which are selected from the group evening primrose oil, echium oil, trichodesma oil, borage oil, seed oil of black currant, hemp oil and / or black cumin oil, of 12% by weight, preferably 16% by weight. . in particular 20% by weight, preferably 24% by weight, particularly preferably 28% by weight, in each case based on the total composition.
  • the agent according to the invention is dye-free.
  • the absence of dyes is particularly advantageous because dyes generally have a clear potential for allergies. There are also large groups of people who have demonstrated allergic reactions to a variety of dyes. In order to reduce the potential for allergies, it is therefore advantageous to minimize the dye content in the agents according to the invention, at best to the extent that the dye is free. If dyes are desired, for example for optical reasons, the usual colorants such. B. pigments, but preferably organic dyes are used. Organic dyes prove to be more skin-friendly in the context of the invention.
  • the dyes and color pigments can advantageously be selected from the corresponding positive list of the Cosmetics Regulation or the EC list of cosmetic colorants. In most cases, they are identical to the colorants approved for food.
  • Advantageous color pigments are, for example, titanium dioxide, mica, iron oxides (eg Fe 2 ⁇ 3, Fe 3 ⁇ 4 , FeO (OH)) and / or tin oxide.
  • Advantageous dyes are, for example, carmine, Berlin blue, chrome oxide green, ultramarine blue and / or manganese violet.
  • the colorant content is preferably below 0.002% by weight of the composition, in particular it is 0% by weight.
  • the agent is in liquid form, in particular emulsified.
  • the water content is preferably between 15 and 75% by weight, preferably 40 to 65% by weight, in particular 45 to 55% by weight, in each case based on the composition.
  • the agent according to the invention is therefore in a non-aqueous form.
  • Non-aqueous form in the context of this invention is understood to mean water contents below 15% by weight, based on the composition, preferably water contents below 10% by weight, particularly preferably below 8% by weight, water contents below 6% by weight. are preferred, but in particular water contents between 2 and 0.001% by weight, based on the composition, are preferred.
  • the advantage of a reduction in the water content in the agent is that the ingredients of the agent according to the invention can be used in a concentrated and thus more effective form during application.
  • the agents according to the invention contain no additional fragrances or perfume oils. It must be noted here that some of the oils already mentioned by name already have a fragrance effect as such. Apart from these natural flavors, such as rosemary oil, there are preferably no additional fragrances or perfume oils in the compositions. This is particularly advantageous since most of these fragrances or perfume oils, which are not skin-healing and / or skin-protecting active substances in the sense of the invention, have an allergy potential which counteracts the present invention. In addition, there are large groups of people who have proven allergic reactions to a large number of such fragrances and / or perfume oils.
  • the agents according to the invention are preferably free from the aforementioned fragrances, it may be desirable to produce a particularly appealing fragrance note that cannot be generated solely from the skin-healing active ingredients according to the invention and their inherent fragrance effects. Therefore, in a preferred embodiment, it is possible to use a small amount of such fragrances that do not contain skin-healing and / or skin-protecting active substances.
  • the meaning of the invention is to add to the relevant means. It must be ensured that no allergic reactions are caused by these additional fragrances.
  • fragrances or fragrances or perfume oils include e.g. synthetic products of the ester, ether, aldehyde, ketone, alcohol and hydrocarbon type.
  • Fragrance compounds of the ester type are e.g. Benzyl acetate, phenoxyethyl isobutyrate, p-tert-butylcyclohexyl acetate, linalyl acetate, dimethylbenzylcarbinyl acetate, phenylethyl acetate, linalylbenzoate, benzyl formate, ethylmethylphenylglycinate, allylcyclohexylpropionate, styrallyl propyl alionate and benyl cyl propylate.
  • the ethers include, for example, benzyl ethyl ether, the aldehydes e.g. the linear alkanals with 8-18 C atoms, citral, citronellal, citronellyloxyacetaldehyde, cyclamenaldehyde, hydroxycitronellal, lilial and bourgeonal, to the ketones e.g.
  • the hydrocarbons mainly include the terpenes such as limonene and pinene.
  • Perfume oils may also contain natural fragrance mixtures, such as those obtainable from plant sources, e.g. Pine oil, muscatel, clove oil, cinnamon leaf oil, linden blossom oil, juniper berry oil, vetiver oil, galbane oil and labdanum oil as well as orange blossom oil, orange peel oil.
  • these latter oils are not skin-healing and / or skin-protecting oils in the sense of the invention.
  • the agents according to the invention additionally contain lactic acid and / or their salts and / or citric acid and / or their salts, in particular their sodium and / or potassium salts.
  • These two skin-friendly acids and / or their salts, especially the lactic acid and their salts serve, among other things, to support or renew the natural protective acid mantle or hydrolyzed film of the skin.
  • the hydrolipid film of the skin is attacked or destroyed by alkaline influences, which results in a loss of the skin's barrier function, so that microorganisms or pollutants can penetrate the skin more easily.
  • the additional lactic acid and / or its salts and / or citric acid and / or its salts, in particular its sodium and / or potassium salts are effective.
  • the additional lactic acid which is already part of the epidermis, also has a stabilizing effect on the acidic pH of the skin (pH approx.5.2) and serves as a moisturizing factor since it can improve the skin's ability to retain water. Lactic acid also has a smoothing effect and supports the detachment of dander.
  • the pH of the agent according to the invention is between 4-6.5, measured at a temperature of 20 ° C., in particular in a 1% aqueous solution or dispersion of the agent. This corresponds to the pH value of the skin of a healthy person.
  • the skin surface is only slightly acidic (pH 5.5 - 6.5), there is a reduced resistance to germs or bacteria, so that it is particularly advantageous in the sense of the invention if the pH of the agent according to the invention is not greater than pH 6.0, measured at a temperature of 20 ° C.
  • Another advantage of this pH range for the agent according to the invention is to be seen in connection with personal hygiene.
  • the body is covered with soap washed, the pH of the washed skin increases to about 9, so that the natural protective coat of the skin is massively disturbed.
  • the skin can use its self-regulating powers to reset the acidic pH. However, this process can take up to 3 hours, but usually at least 30 minutes. This differs from skin type to skin type and runs e.g. B. very small in small children.
  • a skin-friendly pH value is set again more quickly.
  • the pH range mentioned is particularly advantageous with regard to a group of people with particularly sensitive skin, such as babies or toddlers, or a group of people with already existing skin problems, e.g. B. Allergy sufferers.
  • baby skin is considerably thinner than the skin of an adult human. Since the daily production of baby skin is significantly reduced, it only has an incomplete barrier function and a very thin hydrolipid film.
  • the agents according to the invention there is a particular need for the agents according to the invention.
  • the advantage of the agent according to the invention with a pH as described above is that the self-regulating powers of the skin are supported, as far as their alkaline neutralization capacity is concerned, in that the agent which comes into contact with the skin has a skin-optimal pH having.
  • the agent according to the invention supports the natural skin flora of humans.
  • the agents according to the invention can include further moisturizing factors, for example those selected from the following group: amino acids, chitosan or chitosan salts / derivatives, ethylene glycol, glucosamine, glycerol , Diglycerin, triglycerin, uric acid, honey and hardened honey, creatinine, hydrolysis products of collagen, lactitol, polyols and polyol derivatives (e.g.
  • the agent according to the invention is reversibly fixed to a polymeric carrier, e.g. B. via adsorption forces, possibly with the participation of surface-active substances, so that a delayed release of the healing active substances is made possible.
  • a polymeric carrier e.g. B.
  • adsorption forces possibly with the participation of surface-active substances, so that a delayed release of the healing active substances is made possible.
  • Particularly preferred polymeric carriers belong to the class of silicic acid esters. However, it can also be any conceivable other carrier, with the only stipulations that they enable delayed release of active ingredient and as such have no negative or irritating influence on the skin, provided that they are used for the purposes of this invention.
  • the agent according to the invention receives one or more deodorant active ingredients in addition to the healing active ingredients.
  • deodorant active ingredients many of the oils already mentioned by themselves also have a deodorising effect.
  • the particular advantage of adding one or more deodorant active ingredients to the agent according to the invention is that these active ingredients together with the oils mentioned have a particularly enhanced, because synergistic, effect on the deodorant activity.
  • the mode of action consists only in one facet of masking malodorous or unpleasant smells.
  • an additional effect occurs which is based on the synergistic interaction of the healing active substances in the sense of the invention with the added deodorant active ingredient and the self-regulating powers, so that not only the symptom, the bad smell, but the moment that triggers this smell is eliminated.
  • These are usually bacteria that are found in different numbers on the skin or in the hair or pubic hair area. These bacteria can contain proteins and fats, e.g. B. from body sweat, decompose into malodorous short-chain fatty acids. These bacteria are effectively counteracted by the synergistic interaction of the factors mentioned.
  • the skin's self-regulating powers are stimulated and trained.
  • the agent according to the invention is in the form of an emulsion.
  • Emulsions are disperse systems of at least two immiscible liquids, one phase being distributed in the form of fine droplets in the other, coherent phase.
  • macro and micro emulsions and this invention encompasses all types of emulsions.
  • the emulsions according to the invention are prepared by the classic procedures, e.g. B. by shaking, beating, stirring, turbulent mixing, injecting one liquid into another, by emulsifying centrifuges, colloid mills, homogenizers, for example inline machines that work according to the rotor / stator principle, or high-pressure homogenizers that emulsify through sudden pressure release, through vibrations and cavitation in the mixture, and many others.
  • static mixers can also be used, preferably modern micromixers.
  • the emulsions can be stabilized with so-called emulsifiers or stabilizers, so that a possible creaming or sedimentation or the tendency of the dispersed particles to agglomerate is difficult.
  • emulsifiers or stabilizers usually have an amphiphilic character, that is to say they have at least one polar and one non-polar group, and there may also be an excess of the apolar group, in which case one speaks of co-emulsifiers.
  • Saturated or unsaturated, branched or unbranched alkyl radicals and aryl or alkylaryl radicals are generally used as nonpolar groups.
  • anionic, cationic, amphoteric and zwitterionic and nonionic emulsifiers it being possible in principle for all of these emulsifiers to be used in the context of this invention, and also those which do not fit into the aforementioned categories.
  • a physiological and toxicological harmlessness of the emulsifier when used according to the invention is to be observed, which is in accordance with the spirit of the invention, namely to give the skin an advantage.
  • Nonionic emulsifiers are preferably used. All conceivable and customary emulsifying auxiliaries can also advantageously be used according to the invention.
  • oil phase is finely distributed in the water phase, it is an oil-in-water emulsion (O / W emulsion, for example milk), which is preferred according to the invention.
  • O / W emulsion oil-in-water emulsion
  • the basic character of an O / W emulsion is characterized by the water, ie it generally has a less greasy effect on the skin, is rather matting and is absorbed into the skin faster than a W / O emulsion, which can be advantageous.
  • Agents according to the invention can advantageously be formulated as stable O / W preparations for dermatological use according to the invention, for example in the form of creams and ointments which are spreadable in the range from room temperature to skin temperature, or, which is preferred, as lotions or as milk tend to flow in this temperature range.
  • O / W emulsions according to the invention can advantageously be prepared with the aid of conventional O / W emulsifiers, if desired with the aid of W / O emulsifiers or further coemulsifiers.
  • O / W emulsions according to the present invention contain, if required for reasons of stability, one or more emulsifiers, preferably selected from the group of the following substances, which usually act as W / O emulsifiers:
  • Lanolin microcrystalline wax (Cera microcristallina) in a mixture with paraffin oil (Paraffinum liquidum), ozokerite, hydrogenated castor oil, polyglyceryl-3-oleate, wool-wax acid mixtures, wool-wax alcohol mixtures, pentaerythrithyl isostearate, polyglyceryl-3-diisostearate, polyglyceryl Stearic acid, sodium dihydroxycetyl phosphate in a mixture with isopropylhydroxycetyl ether, methyl glucose dioleate, methyl glucose dioleate in a mixture with hydroxystearate and beeswax, mineral oil in a mixture with petrolatum and ozokerite and glyceryl oleate and lanolin alcohol, petrolatum in a mixture with ozokerite and hydrogenated castor oil and glycine oil and glycated oil 3-oleate, PEG-7-hydrogenated castor oil, ozokerite and hydrogenated castor oil,
  • the agents according to the invention contain as emulsifier cetylstearyl alcohol with approx. 30 ethoxy units, preferably eumulgin B3 (cetylstearyl alcohol + 30 ethoxy units), or ethoxylated fatty acid alkanolamides, such as coconut fatty acid monoethanolamide + 4 ethoxy units, which is eumulgin C4 corresponds (both: Cognis Deutschland GmbH).
  • cetylstearyl alcohol with approx. 30 ethoxy units preferably eumulgin B3 (cetylstearyl alcohol + 30 ethoxy units), or ethoxylated fatty acid alkanolamides, such as coconut fatty acid monoethanolamide + 4 ethoxy units, which is eumulgin C4 corresponds (both: Cognis Deutschland GmbH).
  • the O / W emulsions according to the invention contain one or more coemulsifiers, preferably selected from the group of the following substances:
  • silicone emulsifiers can preferably be selected from the group of alkyl methicon copolyols and / or alkyl dimethicone copolyols or other groups of silicone emulsifiers known from the prior art. Dimethicone copolyols are advantageous, for example.
  • the total amount of emulsifiers used according to the invention in the preparations according to the invention is advantageously chosen from the range from 0.05 to 10.0% by weight, preferably 0.1 to 5.0% by weight, based on the total weight of the preparations.
  • Sprayable O / W emulsions in particular O / W microemulsions, are particularly advantageous for the purposes of the present invention.
  • the droplet diameters of ordinary emulsions are preferably in the range from 10 "2 to 10 " 6 cm.
  • Macro emulsions are preferably in the range from approx. 1 ⁇ m to approx. 50 ⁇ m and, without further coloring additives, are milky white and opaque.
  • Such finer macroemulsions usually have a higher viscosity. Appropriate mixtures with particle diameters smaller than preferably about 0.01 ⁇ m appear clear and transparent.
  • microemulsions are in the range of preferably about 50 to about 500 nm. Such microemulsions are colored bluish white to translucent or even transparent and mostly low-viscosity. The viscosity of many O / W type microemulsions is comparable to that of water.
  • microemulsions are that active substances can be present in a much finer disperse in the disperse phase than in the disperse phase of macroemulsions. Another advantage is that their low viscosity makes them easier to spray.
  • both macro and micro emulsions can advantageously be used and produced.
  • the O / W emulsions according to the invention can preferably be stabilized very well against coalescence by thickeners which increase the viscosity of the aqueous phase, in which the finely dispersed particles aggregate again to form larger aggregates and the touching droplets finally flow together.
  • thickeners which increase the viscosity of the aqueous phase, in which the finely dispersed particles aggregate again to form larger aggregates and the touching droplets finally flow together.
  • polyacrylates (carbomer) and / or other organic thickeners are well suited for this purpose.
  • higher-viscosity formulations such as creams or ointments can be produced in an advantageous manner in a stabilized form.
  • Skin lotions generally have a more fluid consistency, characterized by a viscosity that can generally range from about 2000 mPa-s to about 10,000 mPa-s. Due to the considerably greater mobility of the particles, which can bring about faster coalescence, their stability is sometimes more problematic than that of the higher-viscosity formulations.
  • An advantageous embodiment is represented by multiple emulsions, that is to say those which in the droplets of the dispersed or discontinuous phase in turn contain droplets of a further dispersed phase, for example W / O / W emulsions and O / W / O emulsions.
  • the agents according to the invention may contain penetration accelerators.
  • penetration accelerators are substances that accelerate the penetration of the active substances into the skin. These are, for example, phenoxyethanol or phenylethanol.
  • compositions according to the invention contain, in addition to the skin-protecting and / or skin-healing substances according to the invention, one or more additional substances which have an effect on the human organism, eg. B. have the respiratory organs and / or the human psyche.
  • additional substances can of course also be skin-functional and / or skin-protecting in the sense of the attributes according to the invention, but do not need it.
  • Some of the substances already listed, e.g. For example, St. John's wort, lavandin, lemon balm and frankincense not only have a skin-functional effect, they also have a calming or mood-lifting effect on the human psyche.
  • the essential oils of such substances enter the limbic system of the brain via the olfactory bulb (bulbus olfactory) in the nose.
  • the essential oils z. T. without the essential oils have previously been detected by the sense of smell, since the effective concentrations are often below the consciously smellable concentration.
  • This is a clear differentiation from the classic fragrances listed above, for the purpose of which it is essential that they be detected by the sense of smell.
  • it is not a question of producing a pleasant smell, but of producing certain effects on the human organism.
  • substances such as.
  • the absorption takes place via the respiratory tract and the skin.
  • agents according to the invention can be provided which enable a supportive treatment of skin diseases, e.g. B. skin fungus (use of tea tree oil) or physical dysfunctions, such as. B. counteract hyperhidrosis (use of sage)
  • skin diseases e.g. B. skin fungus (use of tea tree oil) or physical dysfunctions, such as. B. counteract hyperhidrosis (use of sage)
  • the agents according to the invention contain one or more active substances from the groups of the waxes, the hydrophobic plant zen extracts, higher fatty acids and esters, essential oils, lipids, vitamins, sunscreens, phospholipids derivatives of alpha-hydroxy acids and / or mixtures of the aforementioned components.
  • the agents according to the invention are in liquid form.
  • the use of both liquid organic solvents and water may be appropriate.
  • the agents according to the invention therefore optionally contain solvents.
  • Solvents which can be used in the agents according to the invention come, for example, from the group of mono- or polyhydric alcohols, alkanolamines or glycol ethers, provided that they are miscible with water in the concentration range indicated.
  • the solvents are preferably selected from ethanol, n- or i-propanol, butanols, glycol, propane or butanediol, glycerol, diglycol, propyl or butyl diglycol, hexylene glycol, ethylene glycol methyl ether, ethylene glycol ethyl ether, ethylene glycol propyl ether, ethylene glycol mono-n-butyl ether, diethylene glycol methyl ether .
  • BPP butoxypropoxy propanol
  • glycol ethers are available under the trade names Arcosolv (Arco Chemical Co.) or Cellosolve, Carbitol or Propasol (Union Carbide Corp.); these also include, for example, butyl carbitol, hexyl carbitol, methyl carbitol R , and carbitol itself, (2- (2-ethoxy) ethoxy) ethanol.
  • Arcosolv Arco Chemical Co.
  • Cellosolve Carbitol
  • Carbitol or Propasol Union Carbide Corp.
  • Pyrrolidone solvents such as N-alkylpyrrolidones, for example N-methyl-2-pyrrolidone or N-C8-Ci2-alkylpyrrolidone, or 2-pyrrolidone, can also be used.
  • N-alkylpyrrolidones for example N-methyl-2-pyrrolidone or N-C8-Ci2-alkylpyrrolidone, or 2-pyrrolidone
  • glycerol derivatives in particular glycerol carbonate.
  • the alcohols which can be used as cosolvents in the present invention include liquid polyethylene glycols with a low molecular weight, for example polyethylene glycols with a molecular weight of 200, 300, 400 or 600.
  • suitable cosolvents are other alcohols, for example (a) lower Alcohols such as ethanol, propanol, isopropanol and n-butanol, (b) ketones such as acetone and methyl ethyl ketone, (c) C2-C4 ⁇ polyols such as a diol or a triol, for example ethylene glycol, propylene glycol, glycerol or mixtures thereof. From the class of diols, 1,2-octanediol is particularly preferred.
  • the agent according to the invention contains one or more solvents from the group comprising Ci to C4 monoalcohols, C2 to C6 glycols, C3 to C-
  • 2-glycol ethers according to the invention contain alkyl or alkenyl groups with less than 10 carbon atoms, preferably up to 8, in particular up to 6, particularly preferably 1 to 4 and extremely preferably 2 to 3 carbon atoms.
  • Preferred C1 to C4 monoalcohols are ethanol, ⁇ -propanol, / so-propanol and terf-butanol.
  • Preferred C2 to C ⁇ glycols are ethylene glycol, 1,2-propylene glycol, 1,3-propylene glycol, 1,5-pentanediol, neopentyl glycol and 1,6-hexanediol, especially ethylene glycol and 1,2-propylene glycol.
  • Ci2 glycol ethers are di-, tri-, tetra- and pentaethylene glycol, di-, tri- and tetrapropylene glycol, propylene glycol monotertiary butyl ether and propylene glycol monoethyl ether as well as the solvents called butoxydiglycol according to INCI, Butoxyethanol, butoxyisopropanol, butoxypropanol, butyloctanol, ethoxydiglycol, ethoxyethanol, ethyl hexanediol, isobutoxypropanol, isopentyldiol, 3-methoxybutanol, methoxyethanol, methoxyisopropanol and methoxymethylbutanol.
  • the agent according to the invention can contain one or more solvents in an amount of usually up to 40% by weight, preferably 0.1 to 30% by weight, in particular 2 to 20% by weight, particularly preferably 3 to 15% by weight , most preferably 5 to 12 wt .-%, each based on the total agent, provided that these solvents do not counter the concern of the invention to promote the well-being of the skin.
  • the agent according to the invention can have further constituents which are usually contained in cosmetic or dermatological preparations such as creams, ointments, gels or lotions.
  • the respective ingredients are well known to the person skilled in the art and it is not difficult for him to select appropriate ingredients and to implement them in a reasonable amount in the agent.
  • the only requirement is that the additional components do not counteract the purpose of the invention to promote the well-being of the skin.
  • Polar oils for example from the group of the lecithins and the fatty acid triglycerides, in particular the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 to 18, carbon atoms can be used.
  • Polar oil components from the group of esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 C atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 can be used C atoms and from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 C atoms.
  • Polar oil components from the group of dialkyl ethers the group of saturated or unsaturated, branched or unbranched alcohols, can be used. It is particularly advantageous to use Guerbet alcohols. Guerbet coals are named after Marcel Guerbet, who described their production for the first time. Guerbet alcohols are obtained from the Guerbet reaction, which is understood to mean the self-condensation of alcohols as a rule under the influence of sodium or copper at temperatures around 200 ° C and elevated pressure. The alcohols thus formed, for example 2-butyl octanol, are referred to as Guerbet alcohols.
  • nonpolar oils which can be used are those which are selected from the group of branched and unbranched hydrocarbons and waxes, in particular petroleum jelly (petrolatum), paraffin oil, squalane and squalene, polyolefins and hydrogenated polyisobutenes.
  • Polydecenes are the preferred substances among the polyolefins.
  • silicone oils Compounds from the group of cyclic and / or linear silicones, which are also referred to as “silicone oils” in the context of the present disclosure, can also be used.
  • phenyltrimethicone can be chosen as the silicone oil.
  • Other silicone oils for example dimethicone, phenyldimethicone, cyclomethicone (octamethylcyclotetrasiloxane), for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane), cetyldimethicone, behenoxydimethicone, can also be used advantageously for the purposes of the present invention.
  • Agents according to the invention can also contain inorganic pigments based on metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular the oxides of titanium (TiO 2 ), zinc (ZnO), iron (e.g. Fe 2 ⁇ 3 ), zirconium (ZrO 2 ), Silicon (SiO 2 ), manganese (eg MnO), aluminum (Al 2 O 3 ), cerium (eg Ce 2 ⁇ 3 ), mixed oxides of the corresponding metals and mixtures of such oxides.
  • These pigments are X-ray amorphous or non-X-ray amorphous. Pigments based on TiO 2 are particularly preferred.
  • the cosmetic and dermatological preparations according to the invention may optionally contain further cosmetic active ingredients, auxiliaries and / or additives, as are usually used in such preparations and are well known to the person skilled in the art from the prior art, for example antioxidants, preservatives, bactericides, Perfumes, substances to prevent foaming, dyes, pigments which have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other customary components of a cosmetic or dermatological formulation such as Alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • auxiliaries and / or additives as are usually used in such preparations and are well known to the person skilled in the art from the prior art, for example antioxidants, preservatives, bactericides, Perfumes, substances to prevent foaming, dyes, pigments which have a coloring effect, thickeners,
  • preservatives or preservation aids customary in cosmetics, such as dibromodicyanobutane (2-bromo-2-bromomethylglutarodinitrile), 3-iodo-2-propynylbutylcarbamate, 2-bromo-2-nitro-propane-1, 3-diol, imidazolidinyl urea, 5- Chloro-2-methyl-4-isothiazoiin-3-one, 2-chloroacetamide, benzalkonium chloride, benzyl alcohol and formaldehyde releasers are conceivable.
  • Phenylhydroxyalkyl ethers in particular the compound known under the name phenoxyethanol, are also suitable as preservatives on account of their bactericidal and fungicidal effects on a number of microorganisms.
  • preservatives are o-cymen-5-ol, 2-bromo-2-nitropropane-1, 3-diol, propylene glycol, chlorphenesin, ethyl, butyl, isobutyl, propyl, methyl paraben, methyl dibromo glutaronitrile, lodopropynyl-
  • Butyl carbamates methyl chloro-, methyl-isothiazolinone, butylene glycol, DMDM hydantoin, imidazolidinyl urea, triclosan, 5-bromo-5-nitro-1, 3-dioxanes, sodium methyl paraben, sodium benzoate and / or sorbic acid and / or mixtures of these, for example, such mixtures as z.
  • anti-irritant or anti-inflammatory active ingredients to the preparations in the context of the present invention, in particular batyl alcohol (octadecylglyceryl ether), salachyl alcohol ( ⁇ -9-octadecenylglyceryl ether), chimyl alcohol ( ⁇ -
  • Hexadecylglyceryl ether Hexadecylglyceryl ether), bisabolol and / or panthenol. It is also advantageous to add customary antioxidants to the preparations according to the present invention, if desired and compatible with the purpose of the invention. According to the invention, all the antioxidants suitable or customary for cosmetic and / or dermatological applications can be used as favorable antioxidants.
  • the antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-camosine, L- Camosin and its derivatives (e.g. anserine), carotenoids, carotenes and their derivatives, chlorogenic acid and their derivatives, aurothioglucose, propylthiouracil and other thiols (e.g.
  • thioredoxin glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, Methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, gamma-linoleyl, cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers , Peptides, lipids, nucleotides, nucleosides and salts) and sulfoximine compounds (e.g.
  • buthionine sulfoximines in very low tolerable dosages (e.g. pmol to ⁇ mol / k g), also (metal) - chelators (e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g.
  • citric acid citric acid, lactic acid, malic acid
  • humic acid bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives
  • unsaturated fatty acids and their derivatives e.g. gamma-linolenic acid, linoleic acid, oleic acid
  • folic acid and their derivatives furfurylidensorbitol and its derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (e.g.
  • Vitamin E tocopherols and derivatives, eg vitamin E-acetate
  • coniferyl benzoate of benzoin ferulic acid, furylidene glucitol, camosin, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguyanic resin acid, nordihydroguajaretic acid, trihydroxybenzoic acid and derivate derivatives and their derivatives and their derivatives and their derivatives and their derivatives , Zinc and its derivatives (eg ZnO, ZnSO4) selenium and its derivatives (eg selenium methionine), stilbene and de- Ren derivatives (for example stilbene oxide, trans-stilbene oxide) and the derivatives suitable according to the invention (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids)
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 10% by weight, particularly preferably 0.05 to 5% by weight, in particular 0.1 to 2% by weight, based on the total weight the preparation.
  • the agent is characterized in that it contains more than 0.03% by weight, in particular 0.05-1% by weight, of natural antioxidants, in particular selected from terpene-containing antioxidants and / or vitamin E (tocopherols and / or derivatives) and / or its derivatives, preference being given to rosemary oil and / or tea tree oil as terpene-containing antioxidants.
  • natural antioxidants in particular selected from terpene-containing antioxidants and / or vitamin E (tocopherols and / or derivatives) and / or its derivatives, preference being given to rosemary oil and / or tea tree oil as terpene-containing antioxidants.
  • hydrocolloids that is to say water-soluble and / or partially water-soluble natural or synthetic polymers which form gels or viscous solutions in aqueous systems.
  • hydrocolloids that is to say water-soluble and / or partially water-soluble natural or synthetic polymers which form gels or viscous solutions in aqueous systems.
  • hydrocolloids that is to say water-soluble and / or partially water-soluble natural or synthetic polymers which form gels or viscous solutions in aqueous systems.
  • organic, fully synthetic compounds such as.
  • xanthan (E 415) is also contained, also called xanthan gum, which is an anionic heteropolysac is charid, which is usually formed by fermentation from corn sugar and isolated as the potassium salt. It is produced by Xanthomonas campestris and some other species under aerobic conditions. Xanthan is formed from a chain with beta-1, 4-bound glucose (cellulose) with side chains. The structure of the subgroups consists of glucose, mannose, glucuronic acid, acetate and pyruvate. The number of pyruvate units determines the viscosity of the xanthane. Kelzan ASX-T (available from: CP Kelco) is particularly suitable.
  • the agent according to the invention is characterized in that it is in the form of an ointment, cream, emulsion, suspension, milk, paste, gel, foam or spray, preferably as a lotion.
  • the character of the lotion can be adjusted via the water content: If the agent contains more than 55% water, it has a milky character, with well below 40% water the creamy properties of the oils predominate.
  • Another object of the invention is the use of an agent for skin treatment according to the invention, characterized in that the agent is in the form of an ointment, cream, emulsion, suspension, milk, paste, gel, foam or spray, preferably as a lotion.
  • a preferred embodiment is the use of an agent according to the invention as a skin care agent, intimate care agent, foot care agent, light stabilizer, shaving agent, after shave lotion, W / O or O / W skin cream and / or lotion, day and night cream and / or lotion, Eye cream and / or lotion, face cream and / or lotion, anti-wrinkle cream and / or lotion, moisturizing cream and / or lotion, vitamin cream and / or lotion, skin lotion, skin care lotion and / or moisturizing lotion, each with a significant improvement in skin tolerance conventional means.
  • Another object of the invention is a product containing an agent according to the invention in liquid form, in particular emulsified, and an application.
  • tion device preferably spray applicator, roller and / or dispenser, with which the agent can be applied to the skin.
  • the spray dispenser is preferably a manually activatable spray dispenser, in particular selected from the group comprising aerosol spray dispensers, self-building spray dispensers, pump spray dispensers and trigger spray dispensers, in particular pump spray dispensers and trigger spray dispensers with a container made of transparent polyethylene or polyethylene terephthalate.
  • Such and similar spray dispensers or related application devices are commercially available and all commercially available spray dispensers or related application devices are suitable for the application according to the invention.
  • the invention further relates to a method for skin treatment in which an effective amount of an agent according to the invention is applied to the skin, preferably using an application device, preferably a spray applicator, roller and / or dosing dispenser.
  • an effective amount is understood to mean an amount which enables the support and promotion of the self-regulating forces of human skin in the sense according to the invention described above. This amount is an individual one that is influenced by many factors such as e.g. B. skin type, degree of damage to the skin, desired or to be achieved result depends.
  • Another object of this invention in a preferred embodiment is the use of at least one skin-protecting and / or skin-healing active ingredient for producing a medically effective dermatological preparation, preferably skin lotion, according to the features of the agent according to the invention which can be found in the description, for supporting irritated and / or sensitized and / or sick human skin and for the prophylactic treatment of healthy skin.
  • a substrate which is impregnated and / or coated and / or impregnated with an agent according to the invention. The design of the impregnating or coating agent or impregnating agent can be found in the description above.
  • the substrate material preferably consists of porous flat cloths. They can consist of a fibrous or cellular flexible material which can retain sufficient amounts of an impregnating or coating agent so that the impregnating or coating agent or impregnating agent is only released to the skin when the substrate comes into contact with the skin and not before , for example during storage.
  • wipes include wipes made of woven and non-woven synthetic and natural fibers, felt, paper or foam, such as hydrophilic polyurethane foam.
  • Nonwovens are generally defined as adhesively bonded fibrous products that have a mat or layered fiber structure, or those that include fiber mats in which the fibers are randomly or randomly distributed.
  • the fibers can be natural, such as wool, silk, jute, hemp, cotton, flax, sisal or ramie; or synthetic, such as rayon, cellulose esters, polyvinyl derivatives, polyolefins, polyamides or polyesters. In general, any fiber diameter or titer is suitable for the present invention.
  • Preferred porous and flat cloths consist of one or different fiber materials, in particular cotton, refined cotton, polyamide, polyester or mixtures of these.
  • the substrates in the form of a cloth have a surface that enables convenient handling by the consumer, for example the cloth surface is 25 cm 2 .
  • the substrates according to the invention can be obtained by impregnating or impregnating the agents according to the invention on a substrate. Accordingly, another object of this invention is a method for treating the skin, in which one or more substrates according to the statements just made are used to rub or contact the skin with it.
  • Example 1 Prescription of a shelf-stable medical lotion
  • the ⁇ -linolenic acid content is at least about 2.52% by weight, based on the entire formulation.
  • Eumulgin B3 cetylstearyl alcohol + 30 ethoxy units
  • Example 2 Prescription of a shelf-stable medical lotion
  • the ⁇ -linolenic acid content is approximately 1.20% by weight, based on the entire formulation.
  • Eumulgin B3 cetylstearyl alcohol + 30 ethoxy units
  • Example 3 Prescription of a shelf-stable, creamy lotion; Production analogous to example 1 Recipe consisting of:
  • the ⁇ -linolenic acid content is at least about 4.14% by weight, based on the entire formulation.
  • Eumulgin C4 (coconut fatty acid monoethanolamide + 4 ethoxy units)
  • Subjects have a slight pre-damage to the skin, the faster regeneration of which was observed by applying the agent compared to an untreated area. Suitable for assessing the (faster) regeneration are z.
  • An effect on the skin can be determined, e.g. B. by a reduction in itching or another effect that strikes the subject with damaged skin and improves his subjective well-being.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une préparation contenant de l'urée et de l'acide gamma -linoléique, cette préparation contribuant au bien-être de la peau et pouvant être appliquée sur celle-ci. Cette préparation apporte à la peau des bienfaits qui dépassent les aspects cosmétiques ou purement sensoriels. L'invention concerne en outre l'utilisation de ladite préparation ainsi qu'un procédé de traitement dermatologique et un substrat imprégné de ladite préparation.
PCT/EP2004/005848 2003-06-10 2004-05-29 Preparation pour la peau Ceased WO2004108107A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04739462A EP1651180A1 (fr) 2003-06-10 2004-05-29 Preparation pour la peau

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2003126010 DE10326010A1 (de) 2003-06-10 2003-06-10 Zubereitung für die Haut
DE10326010.2 2003-06-10

Publications (1)

Publication Number Publication Date
WO2004108107A1 true WO2004108107A1 (fr) 2004-12-16

Family

ID=33494909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/005848 Ceased WO2004108107A1 (fr) 2003-06-10 2004-05-29 Preparation pour la peau

Country Status (3)

Country Link
EP (1) EP1651180A1 (fr)
DE (1) DE10326010A1 (fr)
WO (1) WO2004108107A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1520577A1 (fr) * 2003-09-30 2005-04-06 Kneipp-Werke Kneipp-Mittel-Zentrale GmbH & CO. KG Composition cosmétique ou dermatologique comprenant l'huile d'onagre
WO2006015675A1 (fr) * 2004-08-04 2006-02-16 Henkel Kommanditgesellschaft Auf Aktien Preparation cosmetique pour la peau a base de lipides polyinsatures
WO2006089348A1 (fr) * 2005-01-20 2006-08-31 Kayban Pty Ltd Agent antimicrobien
EP2201942A1 (fr) * 2008-12-23 2010-06-30 Intendis GmbH Composition dotée d'huile de chanvre pour le traitement de maladies topiques
EP2514401A3 (fr) * 2011-01-20 2016-05-18 Henkel AG & Co. KGaA Compositions cosmétiques et dermatologiques contre la peau sèche
FR3037500A1 (fr) * 2015-06-19 2016-12-23 Kala Karite Composition chimique pour dermite
WO2020021175A1 (fr) * 2018-07-24 2020-01-30 Laboratoires M&L Utilisation d'une huile essentielle de rameaux de sapin blanc pour lutter contre les signes du vieillissement cutané

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005026006A1 (de) * 2005-06-03 2006-12-07 Beiersdorf Ag Kosmetische Zubereitungen mit einem Gehalt an einem besonderen Anisfruchtextrakt und Triazin-Lichtfiltern
DE102005026007A1 (de) * 2005-06-03 2006-12-07 Beiersdorf Ag Kosmetische Zubereitungen mit einem Gehalt an einem besonderen Anisfruchtextrakt und sulfonierten Lichtfiltern
DE102006049586A1 (de) * 2006-10-22 2008-04-24 Rudy Susilo Nagellackenferner für kosmetische und medizinische Anwendungen
DE102015110577A1 (de) * 2015-07-01 2017-01-05 Claudia Wirth-Bickel Topische Zubereitung zur Hautpflege

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634152A1 (de) * 1985-10-07 1987-04-09 Rochas Parfums Neue kosmetische oder dermatologische zusammensetzungen, die reich sind an gleichzeitig in form der triglyceride und in freier form oder salzform vorliegenden, essentiellen fettsaeuren
DE4021083A1 (de) * 1990-07-03 1992-01-23 Hans Dr Lautenschlaeger Phospholipidformulierungen und ihre verwendung fuer die zubereitung liposomaler medizinischer und kosmetischer baeder
DE4232140A1 (de) * 1992-09-25 1994-03-31 Medi Concept Unternehmensberat Verfahren und Pflegeset zur Behandlung der Haut bei Neurodermitis
DE4310015A1 (de) * 1993-03-27 1994-09-29 Boerlind Ges Fuer Kosmetische Mittel zur Pflege der menschlichen Haut
DE19715878A1 (de) * 1997-04-16 1998-10-22 Pharmaberatung Fuer Ernaehrung Produkte zur Unterstützung der Behandlung von atopischer Dermatitis
DE19857489A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Ölhaltige Hautschutzpräparate zur Prävention von Hautschäden

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10140586A1 (de) * 2001-08-18 2003-03-06 Beiersdorf Ag Emulsionen mit hohen Gehalten an Antitranspirantien

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634152A1 (de) * 1985-10-07 1987-04-09 Rochas Parfums Neue kosmetische oder dermatologische zusammensetzungen, die reich sind an gleichzeitig in form der triglyceride und in freier form oder salzform vorliegenden, essentiellen fettsaeuren
DE4021083A1 (de) * 1990-07-03 1992-01-23 Hans Dr Lautenschlaeger Phospholipidformulierungen und ihre verwendung fuer die zubereitung liposomaler medizinischer und kosmetischer baeder
DE4232140A1 (de) * 1992-09-25 1994-03-31 Medi Concept Unternehmensberat Verfahren und Pflegeset zur Behandlung der Haut bei Neurodermitis
DE4310015A1 (de) * 1993-03-27 1994-09-29 Boerlind Ges Fuer Kosmetische Mittel zur Pflege der menschlichen Haut
DE19715878A1 (de) * 1997-04-16 1998-10-22 Pharmaberatung Fuer Ernaehrung Produkte zur Unterstützung der Behandlung von atopischer Dermatitis
DE19857489A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Ölhaltige Hautschutzpräparate zur Prävention von Hautschäden

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1520577A1 (fr) * 2003-09-30 2005-04-06 Kneipp-Werke Kneipp-Mittel-Zentrale GmbH & CO. KG Composition cosmétique ou dermatologique comprenant l'huile d'onagre
WO2006015675A1 (fr) * 2004-08-04 2006-02-16 Henkel Kommanditgesellschaft Auf Aktien Preparation cosmetique pour la peau a base de lipides polyinsatures
WO2006089348A1 (fr) * 2005-01-20 2006-08-31 Kayban Pty Ltd Agent antimicrobien
EP1883401A4 (fr) * 2005-01-20 2009-06-10 Kayban Pty Ltd Agent antimicrobien
US9078845B2 (en) 2005-01-20 2015-07-14 Kayban Pty Ltd Anti-microbial agent
EP2201942A1 (fr) * 2008-12-23 2010-06-30 Intendis GmbH Composition dotée d'huile de chanvre pour le traitement de maladies topiques
WO2010072420A2 (fr) 2008-12-23 2010-07-01 Intendis Gmbh Composition comprenant de l'huile de chanvre pour traiter des maladies topiques, en particulier le syndrome mains-pieds
WO2010072420A3 (fr) * 2008-12-23 2010-08-19 Intendis Gmbh Composition comprenant de l'huile de chanvre pour traiter des maladies topiques, en particulier le syndrome mains-pieds
EP2514401A3 (fr) * 2011-01-20 2016-05-18 Henkel AG & Co. KGaA Compositions cosmétiques et dermatologiques contre la peau sèche
FR3037500A1 (fr) * 2015-06-19 2016-12-23 Kala Karite Composition chimique pour dermite
WO2020021175A1 (fr) * 2018-07-24 2020-01-30 Laboratoires M&L Utilisation d'une huile essentielle de rameaux de sapin blanc pour lutter contre les signes du vieillissement cutané
FR3084260A1 (fr) * 2018-07-24 2020-01-31 Laboratoires M&L Utilisation d'une huile essentielle de rameaux de sapin blanc pour lutter contre les signes du vieillissement cutane
KR20210025116A (ko) * 2018-07-24 2021-03-08 라보하뜨와 엠에엘 피부 노화의 징후와 싸우기 위한 화이트 퍼 나무 가지의 에센셜 오일의 용도
CN112739424A (zh) * 2018-07-24 2021-04-30 M&L实验室 白冷杉树树枝精油用于对抗皮肤衰老迹象的用途
KR102344234B1 (ko) 2018-07-24 2021-12-27 라보하뜨와 엠에엘 피부 노화의 징후와 싸우기 위한 화이트 퍼 나무 가지의 에센셜 오일의 용도
CN112739424B (zh) * 2018-07-24 2022-02-11 M&L实验室 白冷杉树树枝精油用于对抗皮肤衰老迹象的用途

Also Published As

Publication number Publication date
DE10326010A1 (de) 2005-01-05
EP1651180A1 (fr) 2006-05-03

Similar Documents

Publication Publication Date Title
DE69725320T2 (de) Oel-im-wasser emulsion zur gruendlichen reinigung, zum schutz oder verbesserung der haut
EP1603999B2 (fr) Agent servant a traiter un textile
DE69600060T2 (de) Silizium-Zusammensetzung, die ein wasserempfindliche Wirkstoff enthält
EP0814753A2 (fr) Gels cosmetiques ou dermatologiques a base de microemulsions
EP2029089B1 (fr) Émulsion h/e pour le soin de la main
DE69614110T2 (de) Stabilisierte pseudoemulsionen und verfahren zu ihrer herstellung
WO2015144333A1 (fr) Émulsions de type aqueux contenant du 4-hydroxyacétophénone et des émulsifiants anioniques
EP1651180A1 (fr) Preparation pour la peau
EP1414398A2 (fr) Preparations cosmetiques ou dermatologiques ayant une action de refroidissement de longue duree
DE102011018924A1 (de) OW-Emulsionskonzentrat, Verfahren zu dessen Herstellung und dieses enthaltendes Hautkosmetikum
EP4185113A1 (fr) Agent désinfectant, toléré par la peau, nourrissant et relipidant, destiné à être appliqué sur la peau
DE102004037753A1 (de) Hautkosmetische Zubereitung
EP1068862A2 (fr) Combinaison de principes actifs déodorants and utilisation
EP1071466A1 (fr) Cremes a base de glycolipide
DE102007043397A1 (de) Wundschutzcremetuch
EP0937454A2 (fr) Compositions cosmétiques ou dermatologiques contenant des polysaccharides pour protéger des irritations les peaux sensibles
EP2717968A2 (fr) Compositions cosmétiques ou dermatologiques sous forme d'émulsions et ayant une libération de parfum améliorée
EP1345583A2 (fr) Lingettes anti-transpiration
JP7234007B2 (ja) 皮膚外用剤
DE10123989A1 (de) Kosmetische und dermatologische Zubereitung zur Beseitigung und Regulation von Sebum
WO2022069124A1 (fr) Chiffon de nettoyage imprégné d'agents d'imprégnation à base d'une émulsion huile dans l'eau
EP1520577A1 (fr) Composition cosmétique ou dermatologique comprenant l'huile d'onagre
EP3482764B1 (fr) Répulsif insectes et/ou arachnides comprenant de l'huile de nigelle
DE102014116691A1 (de) Kosmetische Zusammensetzung und deren Verwendung zur Prophylaxe und Behandlung von Hautunreinheiten, zu Akne neigender Haut und Akne
DE10233598A1 (de) Wirkstoffhaltige kosmetische und/oder dermatologische Zubereitung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004739462

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004739462

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004739462

Country of ref document: EP